PEP-Therapy, a Paris, France-based biotechnology company developing targeted therapies for cancer treatments, raised €1.3m in funding.
Backers included the Quadrivium 1 seed fund managed by Seventure Partners, for €1m, supplemented by a personal investment of €300k from Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier and Founding Chairman of Fondation Fournier-Majoie pour l’Innovation (FFMI).
The company intends to use the funds to undertake regulatory development of its first therapeutic product, associated with a predictive biomarker for foreseeing the effectiveness of the treatment.
The product relies on the innovative technology of bi-functional peptides, which penetrate cells and then specifically block pathological mechanisms, without affecting normal physiological mechanisms.
PEP-Therapy is led by Antoine Prestat, CEO.